aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support ...
Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis. Workforce reduction of approximately 60% and program prioritization conserves capital and …